U.S. Markets close in 1 hr 27 mins
  • S&P 500

    3,629.04
    +51.45 (+1.44%)
     
  • Dow 30

    29,986.49
    +395.22 (+1.34%)
     
  • Nasdaq

    12,021.05
    +140.41 (+1.18%)
     
  • Russell 2000

    1,850.57
    +32.28 (+1.78%)
     
  • Crude Oil

    44.87
    +1.81 (+4.20%)
     
  • Gold

    1,803.00
    -34.80 (-1.89%)
     
  • Silver

    23.25
    -0.38 (-1.62%)
     
  • EUR/USD

    1.1881
    +0.0035 (+0.2970%)
     
  • 10-Yr Bond

    0.8770
    +0.0200 (+2.33%)
     
  • Vix

    21.79
    -0.87 (-3.84%)
     
  • GBP/USD

    1.3350
    +0.0028 (+0.2123%)
     
  • USD/JPY

    104.5550
    +0.0670 (+0.0641%)
     
  • BTC-USD

    19,206.27
    +754.31 (+4.09%)
     
  • CMC Crypto 200

    381.13
    +11.38 (+3.08%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher

Zacks Equity Research
·2 min read

Recro Pharma, Inc. REPH was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $4.34 to $5.26 in the past one-month time frame..

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Recro Pharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Recro Pharma, Inc. Price

Recro Pharma, Inc. Price
Recro Pharma, Inc. Price

Recro Pharma, Inc. price | Recro Pharma, Inc. Quote

Investors interested in the Medical – Drugs industry may consider Avenue Therapeutics, Inc. ATXI, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Recro Pharma, Inc. (REPH) : Free Stock Analysis Report
 
Avenue Therapeutics, Inc. (ATXI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research